SCHEMBL23358345

SCHEMBL23358345

C[C@H](NP(=O)(Oc1ccc(Br)cc1)Oc1ccc([N+](=O)[O-])cc1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 9/20 0.47
▸ KMT2A Q03164 9/20 0.47
▸ POLB P06746 1/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ CES2 O00748 1/20 0.47
▸ CES1 P23141 1/20 0.47
▸ ALDH1A1 P00352 5/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MAPT P10636 4/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ BCHE P06276 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23358321 1.00 MEN1 (0.47) MEN1KMT2APOLBCA1CA2
SCHEMBL23358320 1.00 MEN1 (0.47) MEN1KMT2APOLBCA1CA2
SCHEMBL15635076 0.94 CA1 (0.53) MEN1KMT2ACA1CA2CES2
SCHEMBL17760460 0.91 ALDH1A1 (0.50) MEN1KMT2APOLBCA1CA2
SCHEMBL17712319 0.91 ALDH1A1 (0.50) MEN1KMT2APOLBCA1CA2
SCHEMBL15536216 0.91 ALDH1A1 (0.50) MEN1KMT2APOLBCA1CA2
SCHEMBL23803197 0.91 ALDH1A1 (0.50) MEN1KMT2APOLBCA1CA2
SCHEMBL23803196 0.91 ALDH1A1 (0.50) MEN1KMT2APOLBCA1CA2
SCHEMBL15536414 0.91 ALDH1A1 (0.50) MEN1KMT2APOLBCA1CA2
SCHEMBL14989437 0.91 ALDH1A1 (0.50) MEN1KMT2APOLBCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202850-B2 Cyclobutyl purine derivative or salt thereof FUJIFILM CORPORATION (JP) 2025-01-21 — — US disclosed
EP-3831388-B1 CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF FOR USE IN SUPPRESSING ADENOVIRUS FUJIFILM CORP (JP) 2024-02-28 — — EP disclosed
US-20230295202-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2023-09-21 — — US disclosed
EP-3831836-B1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM CORP (JP) 2023-09-06 — — EP disclosed
EP-3831388-A1 CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM Corporation (JP) 2021-06-09 — — EP disclosed
EP-3831836-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM Corporation (JP) 2021-06-09 — — EP disclosed
US-20210155644-A1 CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2021-05-27 — — US disclosed
US-20210147456-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295202-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF SLC28A1, SLC20A1, SLC29A1 MEN1 2712/4885KMT2A 4442/4885POLB 141/4885
US-20210147456-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF SLC28A1, SLC20A1, SLC29A1 MEN1 2712/4885KMT2A 4442/4885POLB 141/4885
US-12202850-B2 Cyclobutyl purine derivative or salt thereof SLC28A1, SLC20A1, SLC29A1 MEN1 2712/4885KMT2A 4442/4885POLB 141/4885
US-20210155644-A1 CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF SLC28A1, SLC20A1, NOX1 MEN1 2904/4885KMT2A 4547/4885POLB 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback